Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease
June 11, 2021 07:00 ET
|
Equillium
Itolizumab continues to demonstrate favorable safety and efficacy profile Rapid and durable responses resulted in clinically meaningful reduction in corticosteroid use Data support clinical...
Equillium to Host Conference Call Following Presentation of Data from the EQUATE Study in Acute Graft Versus Host Disease at the EHA2021 Virtual Congress of the European Hematology Association on June 11
June 03, 2021 08:00 ET
|
Equillium
Presentation and conference call will include topline data from all cohorts The risk-benefit profile observed supports advancing development of itolizumab in first-line therapy LA JOLLA,...
Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association
May 13, 2021 08:00 ET
|
Equillium
LA JOLLA, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation
March 15, 2021 08:00 ET
|
Equillium
EQUATE acute graft-versus host disease (aGVHD) study observed rapid response and durability through day 85 EQUATE aGVHD study reported a clinically meaningful reduction in corticosteroid...
Equillium to Present at the SVB Leerink 10th Annual Global Healthcare Conference
February 18, 2021 08:00 ET
|
Equillium
LA JOLLA, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience
February 12, 2021 15:00 ET
|
Equillium
Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial reduction in baseline corticosteroid use Dose-dependent reduction of CD6 expression on CD4+ and CD8+ T cells is...
Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT Meetings Digital Experience
January 22, 2021 08:00 ET
|
Equillium
LA JOLLA, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium to Host Virtual Investor and Analyst Day on December 4, 2020
November 30, 2020 08:00 ET
|
Equillium
Review positive interim data from the study of itolizumab for the treatment of acute GVHD and pipeline programs in lupus / lupus nephritis and uncontrolled asthma Featured guest speaker: John...
Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease
November 06, 2020 08:35 ET
|
Equillium
100% overall response rate in dose cohort 3 and 80% overall response rate across all cohorts to date Complete response observed in seven of eight responding patients EQUATE Phase 1b topline data...
Equillium Reports Second Quarter 2020 Financial Results and Recent Highlights
August 12, 2020 08:37 ET
|
Equillium
LA JOLLA, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...